Respiratory Medicine and Research最新文献

{"title":"The impact of deep venous thrombosis on 90 day mortality in chronic obstructive pulmonary disease patients presenting with pulmonary embolism","authors":"Sinem Nedime Sökücü ,&nbsp;Celal Satıcı ,&nbsp;Fatma Tokgöz Akyıl ,&nbsp;Nurdan Şimşek Veske ,&nbsp;Fatma Elif Koçal ,&nbsp;Seda Tural Önür ,&nbsp;Cengiz Özdemir","doi":"10.1016/j.resmer.2024.101090","DOIUrl":"10.1016/j.resmer.2024.101090","url":null,"abstract":"<div><h3>Background</h3><p>There are a limited number of studies investigating the effect of deep venous thrombosis (DVT) in patients presenting with both pulmonary embolism and chronic obstructive pulmonary disease. The aim of this study is to investigate the prevalence and prognostic significance of DVT in patients with PE-COPD.</p></div><div><h3>Methods</h3><p>COPD patients admitted with a diagnosis of PE to our tertiary hospital between January 2016 and January 2021 were retrospectively evaluated with an electronic hospital database. Univariate and multivariate Cox regression analyses were performed to reveal independent prognostic factors.</p></div><div><h3>Results</h3><p>Two hundred thirty-three patients (mean age 65.1 ± 12.2, 158 men (67.5 %)) were included. DVT was present at the time of diagnosis in 45 (19.31 %) of the patients. Patients with DVT tend to have more comorbidities, central pulmonary embolism, higher CRP and <span>d</span>-dimer levels, and SPESI score (<em>p</em>&lt;0.05). After performing multivariate analyses, the presence of DVT (HR=3.48, CI: 1.02- 11.88, <em>p</em> = 0.046), ischemic heart disease (HR=3.82, CI: 1.38- 10.80, <em>p</em> = 0.01), and malignancy (HR=4.85, CI: 1.53- 15.41, <em>p</em> = 0.007) were found to be independent factors in predicting 90-day mortality.</p></div><div><h3>Conclusions</h3><p>In PE-COPD patients, co-existing DVT may predict a worse outcome.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"85 ","pages":"Article 101090"},"PeriodicalIF":2.3,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139890607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative DLCO predicts severe early complications after liver transplantation","authors":"Xing Li ,&nbsp;Louise Barbier ,&nbsp;Martine Ferrandière ,&nbsp;Francis Remerand ,&nbsp;Ephrem Salamé ,&nbsp;Laurent Plantier","doi":"10.1016/j.resmer.2024.101089","DOIUrl":"10.1016/j.resmer.2024.101089","url":null,"abstract":"<div><h3>Background</h3><p>Severe early complications are common after liver transplantation (LT) and are a key determinant of LT-related morbidity and mortality. The aim of this study was to assess whether lung function measured in the pre-operative period predicted complicated outcomes in the first month after LT.</p></div><div><h3>Material and methods</h3><p>Patients with mild-to-moderate liver disease (Model for End stage Liver Disease-MELD score≤30) who underwent LT between October 2015 and May 2020 in a single centre were retrospectively included. The primary endpoint was the occurrence of severe early complications after LT defined by mechanical ventilation duration &gt; 2 days or length of ICU stay &gt; 7 days or reintubation or death &lt; 1 month after LT.</p></div><div><h3>Results</h3><p>One hundred and twenty patients were included (age 59 [53–64] years, 72 % men). Forty patients (33 %) had early complications after LT. Measured and%predicted hemoglobin-corrected lung transfer capacity for carbon monoxide (DLCOc) were significantly lower in patients with severe early complications after LT. DLCOc was the only variable that associated independently with severe early complications by multivariate analysis. DLCOc under 16.3 ml.min⁻¹.mmHg⁻¹ predicted respiratory complications with a sensitivity of 67.5 % and a specificity of 62.9 %. DLCOc%pred under 61.5 % had a sensitivity of 56.8 % and a specificity of 72 %. DLCOc independently associated with forced vital capacity (FVC), pulmonary emphysema, and the muscle mass index.</p></div><div><h3>Conclusion</h3><p>A decrease in DLCOc indicated an increased risk of severe early complications after LT.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"85 ","pages":"Article 101089"},"PeriodicalIF":2.3,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590041224000060/pdfft?md5=614c65798150cc8937a5874c9e9289ea&pid=1-s2.0-S2590041224000060-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139893046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Residual reversibility in COPD patients already on long-acting bronchodilator: The OscilloRevers Study","authors":"Olivier Le Rouzic ,&nbsp;Marjorie Picaud ,&nbsp;Hélène Salvator ,&nbsp;Nathalie Bautin ,&nbsp;Philippe Devillier ,&nbsp;Thierry Perez","doi":"10.1016/j.resmer.2023.101082","DOIUrl":"10.1016/j.resmer.2023.101082","url":null,"abstract":"<div><h3>Background</h3><p>Dyspnea is a complex symptom of chronic obstructive pulmonary disease<span><span> (COPD) which is not strongly correlated with lung function measures. Long-acting bronchodilators (LAB) may reduce this dyspnea, but some patients report persistent chronic dyspnea despite this </span>treatment. This study aims to assess residual reversibility and clinical response after short-acting bronchodilator (SAB) in COPD patients already treated by LAB and reporting persistent dyspnea.</span></p></div><div><h3>Methods</h3><p><span><span>COPD patients with a persistent dyspnea (modified Medical Research Council scale (mMRC) ≥1) despite current stable treatment with at least one LAB were included. </span>Spirometry, </span>plethysmography<span> and impulse oscillometry<span> (IOS) were performed at peak effect of their LAB and repeat 45 min after the intake of two SAB (400 µg of salbutamol and 80 µg of ipratropium). Dyspnea improvement was assessed at 45 min after SAB through a comparative two-sided VAS (-100 mm for maximal improvement; +100 mm for maximal degradation).</span></span></p></div><div><h3>Results</h3><p>Twenty-two COPD patients were analyzed, mainly men (59.1 %) with a mean age of 60.6 years and a median FEV1 of 54 % of predicted values. Fifty percent of patients reported a severe basal dyspnea (mMRC ≥2). After SAB, spirometric and plethysmographic measurements were statistically improved. For IOS measurement, reactance at 5 Hz (X5) and area of reactance (AX) were also improved. Fifty percent of patients reported a clinically relevant improvement of their resting dyspnea. However, no correlation was found between dyspnea improvement and functional measures.</p></div><div><h3>Conclusions</h3><p>Fifty percent of COPD patients regularly treated with one or two LAB still report a relevant improvement of resting dyspnea after the adjunctive intake of double short-acting bronchodilators. Physiological mechanisms associated with this improvement remain to be determined.</p></div><div><h3>Clinical Trial Registration</h3><p>NCT02928744</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"85 ","pages":"Article 101082"},"PeriodicalIF":2.3,"publicationDate":"2024-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139570163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Profiles, diagnostic process, and patterns of care of patients with stage III non-small cell lung cancer: A French national study","authors":"Jean-Bernard Auliac ,&nbsp;Laurent Greillier ,&nbsp;Etienne Martin ,&nbsp;Pierre-Emmanuel Falcoz ,&nbsp;Pierre Boisselier ,&nbsp;Sabine Ano ,&nbsp;Marc Lefrançois ,&nbsp;Alexis Cortot","doi":"10.1016/j.resmer.2024.101087","DOIUrl":"10.1016/j.resmer.2024.101087","url":null,"abstract":"<div><h3>Background</h3><p>The management of stage III non-small-cell lung cancer (NSCLC) remains heterogeneous and complex, even after the approval of immune checkpoint inhibitors post-chemoradiotherapy (CRT). This observational study from France evaluated real-world practices in managing stage III NSCLC.</p></div><div><h3>Methods</h3><p>Between 2020 and 2022, we conducted a physician practice survey in 41 medical centers across France, and retrospectively analyzed aggregated information from 417 consecutive charts of patients with stage III NSCLC. We collected information on diagnostic and staging procedures, biomarker testing, surgical and non-surgical treatments, and follow-up.</p></div><div><h3>Results</h3><p>According to the physician survey, diagnostic workup of stage III NSCLC primarily relied on positron emission tomography/computed tomography and brain magnetic resonance imaging, performed for the majority of patients in 100 % and 78 % of centers, respectively. Of 417 patient charts, 414 were evaluable with 53 % of patients having stage IIIA disease, 37 % IIIB, and 10 % IIIC. The most common node involvement was N2 (59 %). Programmed death-ligand 1 testing was conducted for 98 % of patients. Invasive staging (mediastinoscopy or endobronchial ultrasound) was performed in 41 % of patients, of whom 83 % had N2 or N3 nodal involvement. Surgical resection was offered to 120 patients (29 %), with 85 % achieving R0 resection. In 292 charts of patients with unresectable stage III NSCLC, 190 patients (65 %) were offered CRT followed by consolidation immunotherapy. Within these patients, concurrent CRT was more frequently employed (52 %) than sequential CRT (13 %).</p></div><div><h3>Conclusions</h3><p>Diagnostic procedures and treatment modalities in French medical centers generally align with clinical guidelines for stage III NSCLC, except for invasive staging that was less commonly performed than expected.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"85 ","pages":"Article 101087"},"PeriodicalIF":2.3,"publicationDate":"2024-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139633253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High prevalence of circulating myositis-associated antibodies in non-COVID critical illness","authors":"Alyssa Soskis ,&nbsp;Mary B. Rice ,&nbsp;Donald B. Bloch ,&nbsp;Rachel K. Putman ,&nbsp;Antonio Arciniegas Rubio ,&nbsp;Katherin Zambrano Vera ,&nbsp;Rene S. Bermea ,&nbsp;Andrew J. Sauer ,&nbsp;Claire O. Sinow ,&nbsp;Max Shen ,&nbsp;Mayra Pinilla Vera ,&nbsp;Rebecca M. Baron ,&nbsp;Robert W. Hallowell","doi":"10.1016/j.resmer.2024.101088","DOIUrl":"10.1016/j.resmer.2024.101088","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"85 ","pages":"Article 101088"},"PeriodicalIF":2.3,"publicationDate":"2024-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590041224000059/pdfft?md5=85ca719f47ef99aebcbe14fb0b52f9c9&pid=1-s2.0-S2590041224000059-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139632353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential availability of saliva-based reverse transcription-quantitative polymerase chain reaction in extensive screening for asymptomatic individuals as a business continuity strategy during the coronavirus disease 2019 pandemic","authors":"Noriko Tomita ,&nbsp;Moto Kimura ,&nbsp;Yukari Uemura ,&nbsp;Yukumasa Kazuyama ,&nbsp;Masato Ikeda ,&nbsp;Wataru Sugiura","doi":"10.1016/j.resmer.2024.101085","DOIUrl":"10.1016/j.resmer.2024.101085","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"85 ","pages":"Article 101085"},"PeriodicalIF":2.3,"publicationDate":"2024-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139540439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidental diagnosis of lung cancer on chest CT scan performed for suspected or documented COVID-19 infection","authors":"Pascal Wang ,&nbsp;Patricia Martel ,&nbsp;Mostafa El Hajjam ,&nbsp;Lamiae Grimaldi ,&nbsp;Etienne Giroux Leprieur ,&nbsp;’AP-HP / Universities / Inserm COVID-19 research collaboration and AP-HP Covid CDW Initiative","doi":"10.1016/j.resmer.2024.101084","DOIUrl":"10.1016/j.resmer.2024.101084","url":null,"abstract":"<div><h3>Context</h3><p>Recent studies have shown a benefit of chest computed tomography (CT scan) in lung cancer screening. The COVID-19 pandemic has led to many chest CT scan performed on a large population. The objective of this study was to describe the incidence and characteristics of lung cancer detected on chest CT scan, outside the framework of a clinical trial, for a suspected or documented COVID-19 infection.</p></div><div><h3>Methods</h3><p>We conducted a multicenter study, carried out from the analysis of data from the prospective COVID-19 database of the Clinical Data Warehouse of the Greater Paris University Hospitals (AP-HP). We identified the patients who had been diagnosed with a lung cancer, due to a chest CT scan done for a suspected or confirmed COVID-19 infection. The study period was limited to the first two epidemic lockdowns: (03/01/20 - 05/31/20) and (10/10/20 - 11/30/20).</p></div><div><h3>Results</h3><p>Over the study period, 24 390 patients had at least one chest CT scan. Among them, 72 lung cancer diagnoses were made (incidence 0.30 %; median age 67.4 years old, 50.0 % current smokers, 55.6 % adenocarcinoma). Half of the lung cancer patients (<em>n</em> = 36) did not meet the <em>National Lung Screening Trial</em> inclusion criteria. Twenty-six patients (36.1 %) were diagnosed at an early stage, 25 (34.7 %) of whom received radical curative treatment. Twenty-six patients died during the follow-up (36.1 %) but none in early stages. The median overall survival in lung cancer patients was 693 days [532 – NA].</p></div><div><h3>Conclusions</h3><p>A large-scale chest CT scan strategy for suspected or documented COVID-19 infection has allowed a significant proportion of early-stage lung cancer diagnosis, all of which have benefited from curative treatment.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"85 ","pages":"Article 101084"},"PeriodicalIF":2.3,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590041224000011/pdfft?md5=6b078ded0881448f2735d0aa929b2d38&pid=1-s2.0-S2590041224000011-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140519720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic and Therapeutic Role of Electrocautery Snare Use in Endobronchial Polypoid Lesions","authors":"Banu Kahriman ,&nbsp;Celal Satici ,&nbsp;Sinem Nedime Sokucu ,&nbsp;Levent Dalar ,&nbsp;Cengiz Ozdemir","doi":"10.1016/j.resmer.2023.101074","DOIUrl":"10.1016/j.resmer.2023.101074","url":null,"abstract":"<div><h3>Introduction</h3><p>Electrocautery with a snare probe offers a tool for the treatment of endobronchial polyps. The aim of this study was to demonstrate the efficacy of the snare probe in patients undergoing rigid bronchoscopy due to central airway obstruction.</p></div><div><h3>Methods</h3><p>This retrospective descriptive study included patients who underwent rigid bronchoscopy with an electrocautery snare probe for the diagnosis and/or treatment of endobronchial polyps in an interventional pulmonology unit.</p></div><div><h3>Results</h3><p>The mean age of the 47 patients (38 men) with endobronchial polypoid lesions was 61.5 years. Six lesions (12.8%) were located in the trachea, 6 (12.8%) in the right main bronchus, 11 (23.4%) in the left main bronchus, and 24 (51.1%) in the lobar bronchi. Twenty-eight lesions (59.5%) were malignant. Prior to the procedure, 6 (12.8%) patients had grade 1 obstruction, 6 (12.8%) had grade 2 obstruction, 15 (31.9%) had grade 3 obstruction, and 20 (42.6%) had grade 4 obstruction. In terms of airway obstruction after the procedure, grade 1 was present in 46 (97.9%) patients and grade 2 was present in 1 (2.1%) patient. No major complication developed in 93.6% of the patients. During a mean follow-up period of 48 months, 85.1% of the patients did not experience recurrence.</p></div><div><h3>Conclusion</h3><p>Our results demonstrate that the snare probe can be used to effectively and reliably establish airway patency in patients with central airway obstruction due to endobronchial polypoid lesions.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"85 ","pages":"Article 101074"},"PeriodicalIF":2.3,"publicationDate":"2023-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139194731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Residual upper airway obstruction during nocturnal noninvasive ventilation despite high positive expiratory pressure. Impact of oronasal mask to nasal mask switch","authors":"Pierre Tankéré ,&nbsp;Marjolaine Georges ,&nbsp;Caroline Abdulmalak ,&nbsp;Deborah Schenesse ,&nbsp;Guillaume Beltramo ,&nbsp;Amaury Berrier ,&nbsp;Philippe Bonniaud ,&nbsp;Claudio Rabec","doi":"10.1016/j.resmer.2023.101083","DOIUrl":"10.1016/j.resmer.2023.101083","url":null,"abstract":"<div><h3>Background</h3><p><span>Nasal mask (NM) and oronasal masks (OM) can be used to provide noninvasive ventilation (NIV). Recent studies suggested that OM is the most used interface and that there is no difference in efficacy or in tolerance between OM and NM for chronic use. However, studies focusing on video laryngoscopy underlined the impact of OM in residual upper airway obstruction (UAO) under </span>NIV<span>. We sought to assess the real-life practice of switching from OM to NM when UAO events persist despite high EPAP levels.</span></p></div><div><h3>Methods</h3><p>In an open-label single center prospective cohort study, data from files and full night polysomnography on NM and OM were collected for patients wearing OM and presenting an UAO index ≥15/h despite an EPAP level ≥ 10 cmH20.</p></div><div><h3>Results</h3><p>Forty-four patients were included in the study. In 31 patients (74 %), switching to a NM reduced UAOi to ≥10/h. Interestingly, 92 % of these patients still had NM at 3 to 12 months of follow-up. Switching to a NM was also associated with a trend in paCO2 reduction and significant improvements in Epworth, sleep quality and NIV compliance. Successful interface switching was significantly associated with female gender, and a trend was observed in non-smokers.</p></div><div><h3>Conclusion</h3><p>As for CPAP, switching to a NM improved NIV efficacy in a selected group of patients presenting residual UAO events despite high EPAP levels. Additionally, this switch has an impact on compliance and subjective sleepiness. Thus, in patients with persisting UAO on OM, switching to a NM could be a first-line intervention before considering further investigation such as polygraphy or video laryngoscopy. We also derive an algorithm for mask allocation and adaptation in acute and chronic NIV use.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"85 ","pages":"Article 101083"},"PeriodicalIF":2.3,"publicationDate":"2023-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139192192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-mutated citrullinated vimentin antibodies are increased in IPF patients","authors":"Pierre Le Guen ,&nbsp;Coralie Tardivon ,&nbsp;Cédric Laouénan ,&nbsp;Marie-Pierre Debray ,&nbsp;Pascale Nicaise Roland ,&nbsp;Camille Taillé ,&nbsp;Raphael Borie ,&nbsp;Sébastien Ottaviani ,&nbsp;Andreas Guenther ,&nbsp;Philippe Dieudé ,&nbsp;Bruno Crestani","doi":"10.1016/j.resmer.2023.101081","DOIUrl":"10.1016/j.resmer.2023.101081","url":null,"abstract":"<div><h3>Intro</h3><p>An increased prevalence of serum anti-MCV antibody is observed in the serum of patients with idiopathic pulmonary fibrosis (IPF) but the clinical relevance of these antibodies is unknown.</p></div><div><h3>Methods</h3><p>Patients from our center with a diagnosis of IPF according to the 2018 ATS/ERS/JRS/ALAT guidelines and at least one anti-MCV assay available were selected. All patients were part of the prospective cohort European IPF registry and selected between 03/2010 and 03/2018. We constituted two groups of patients according to the anti-MCV status at baseline to compare their characteristics at baseline and the evolution of lung function, survival and/or transplantation status.</p></div><div><h3>Results</h3><p>Anti-MCV data were available for 101 patients, of whom 86 had complete clinical data available. Twenty-nine (34 %) patients had a positive anti-MCV assay (MCV+), at a low level in most patients (29 UI/mL [IQR 25—40]), and 57 (66 %) patients a negative assay (MCV-). MCV+ patients were 20 men and 9 women, with a median age of 73 years [IQR 67—78]. MCV- patients were 49 men and 8 women with a median age of 72 years [IQR 64—77]. Sixty-two (75 %) patients were ex-smokers and 5 (6 %) were active smokers. Median cumulative tobacco smoke exposure was 22.5 (15.0–38.6) and was similar in both groups. Lung function test results and HRCT pattern distribution was similar in both groups at baseline. The median duration of follow-up was 3.5 years [IQR 2.1—5.0]. Lung function decline was similar in both groups. During the study period, 31 (36 %) patients died or have been transplanted with no difference in transplant-free survival status between the two groups.</p></div><div><h3>Conclusion</h3><p>Low level anti-MCV autoimmunity was prevalent in IPF patients</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"85 ","pages":"Article 101081"},"PeriodicalIF":2.3,"publicationDate":"2023-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138987139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}